References
  1. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000;342:1334–49.
  2. Cell Death & Differentiation COVID-19 infection: the perspectives on immune responses Yufang Shi1, Ying Wang Changshun Shao, Jianan Huang, Jianhe Gan, Xiaoping Huang, Enrico Bucci, Mauro Piacentini, Giuseppe Ippolito, Gerry Melino
  3. Baggiolini M, Walz A, Kunkel SL. Neutrophil-activating peptide-1/ interleukin-8: a novel cytokine that activates neutrophils. J Clin Invest 1989;84:1045–9.
  4. Standiford TJ, Rolfe MW, Kunkel SL, et al. Macrophage inflammatory protein-1: expression in interstitial lung disease. J Immunol 1993;151:2852–63.
  5. Suter PM, Suter S, Girardin E, Roux-Lombard P, Grau GE, Dayer JM.High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interkeukin-1, interferon, and elastase, in patients with respiratory distress syndrome after trauma, shock, or sepsis . Am Rev Respir Dis 1992;145:1016–22.
  6. Siler TM, Swierkosz JE, Hyers TM, Fowler AA, Webster RO.Immunoreactive interleukin-1 in bronchoalveolar lavage fluid of high-risk patients and patients with the adult respiratory distress syndrome. Exp Lung Res 1989;15:881–94.
  7. Goodman RB, Strieter RM, Martin DP, et al. Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome. Am J Respir Crit Care Med 1996;154:602–11.
  8. Park WY, Goodman RB, Steinberg KP, et al. Cytokine balance in the lungs of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2001;164:1896–903.
  9. Donnelly SC, Strieter RM, Reid PT, et al. The association between mortality rates and decreased concentrations of interleukin-10 and interleukin-1 receptor antagonist in the lung fluids of patients with the adult respiratory distress syndrome. Ann Intern Med 1996;125:191–6.
  10. Arend WP, Joslin FG, Thompson RC, Hannum CH. An IL-1 inhibitor from human monocytes: production and characterization of biologic properties. J Immunol 1989;143:1851–8.
  11. Arend WP. Interleukin-1 receptor antagonist. Adv Immunol 1993;54:167–227.
  12. Burger D, Chicheportiche R, Giri JG, Dayer JM. The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. J Clin Invest 1995;96:38–41.
  13. Conti P Ronconi GCaraffa A Gallenga CE Ross RFrydas I Kritas SK. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. Masters PS, Perlman, S (2013) Coronaviridae. In: Knipe DM, Howley P (eds) Fields Virology. Lippincott Williams and Wilkins, Philadelphia, PA, pp 825–858.
  14. THE LANCET Infectious Diseases Vol 3 November 2003 Effects of chloroquine on viral infections: an old drug against today’s diseases? Andrea Savarino, Johan R Boelaert, Antonio Cassone, Giancarlo Majori, and Roberto Cauda.
  15. J.Benhamou, Ori-Michael; Geva, Shahar; Jacobs, Miriam; Drew, Jonathan; Waldman, Maor; Kalchiem-Dekel, The Use of Colchicine in Respiratory DiseasesOr Current Respiratory Medicine Reviews, Volume 9, Number 5, 2013, pp. 300-304(5)
  16. Front. Pharmacol., 16 August 2019 The Association Between Usage of Colchicine and Pneumonia: A Nationwide, Population-Based Cohort Study
  17. ”Colchicine Monograph for Professionals”. Drugs.com. American Society of Health-System Pharmacists. Retrieved 27 March 2019.
  18. Schachner, Lawrence A.; Hansen, Ronald C. (2011).Pediatric Dermatology E-Book. Elsevier Health Sciences. p. 177. ISBN 9780723436652.
  19. Hutchison, Stuart J. (2009).Pericardial Diseases: Clinical Diagnostic Imaging Atlas with DVD. Elsevier Health Sciences. p. 58. ISBN 9781416052746.
  20. ”Colchicine for acute gout: updated information about dosing and drug interactions”. National Prescribing Service, Australia. 14 May 2010. Archived from the original on 30 June 2012. Retrieved 14 May 2010.
  21. Dalbeth N, Lauterio TJ, Wolfe HR (October 2014).”Mechanism of action of colchicine in the treatment of gout”. Clinical Therapeutics. 36 (10): 1465–79.
  22. Chen LX, Schumacher HR (October 2008). ”Gout: an evidence-based review”. Journal of Clinical Rheumatology. 14 (5 Suppl): S55-62.
  23. ”Colcrys (colchicine, USP) tablets 0.6 mg. Drug Approval Package”. US Food and Drug Administration. 17 February 2010. Retrieved 19 August 2018.
  24. ”Information for Healthcare Professionals: New Safety Information for Colchicine (marketed as Colcrys)”. U.S. Food and Drug Administration.
  25. Van Echteld I, Wechalekar MD, Schlesinger N, Buchbinder R, Aletaha D (August 2014).”Colchicine for acute gout”. The Cochrane Database of Systematic Reviews. 8 (8): CD006190.
  26. Alabed S, Cabello JB, Irving GJ, Qintar M, Burls A (August 2014).”Colchicine for pericarditis” . The Cochrane Database of Systematic Reviews.8 (8): CD010652.
  27. Portincasa P (2016).”Colchicine, Biologic Agents and More for the Treatment of Familial Mediterranean Fever. The Old, the New, and the Rare”.Current Medicinal Chemistry. 23 (1): 60–86.